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ABSTRACT: This paper describes the application of a novel
antisolvent crystallization approach to rapid production of
tunable solid solutions of hydrophobic amino acids, comprising
L-leucine, L-isoleucine, and L-valine. The antisolvent approach
provides an alternative to other crystallization routes, e.g., ball-
milling, liquid-assisted grinding, and slurry methods, to achieve
the required multicomponent solid phases. We report new
crystal structures of L-leucine/L-isoleucine and L-leucine/L-
valine, and conﬁrm a recent report on a new form of L-
isoleucine/L-valine. We used these multicomponent complexes
as a test set of materials to demonstrate translation of small scale
batch antisolvent crystallization to a continuous production
process.
■ INTRODUCTION
Multicomponent complexes (MCCs) are materials that have
two or more diﬀerent molecules in the same crystal lattice.1,2
MCCs can be classiﬁed into many diﬀerent subsets that include
cocrystals, solvates, and solid solutions. The interest in MCCs
recently led to cocrystals being classiﬁed by the U.S. Food and
Drug Administration for the ﬁrst time to clarify their legal
status.3,4 Initially cocrystals were classiﬁed as “cocrystal drug
product intermediates” rather than new active pharmaceutical
ingredients (APIs); however they have recently been
reclassiﬁed as a special case of a solvated product where the
second component is nonvolatile.5 MCCs in their various forms
are products of crystal engineering, an area of science that has
opened up the opportunity to design and tune the properties of
materials such as luminescence,6,7 detonation velocity,8
bioavailability,9 stability,10,11 phase transition temperatures,12
and processability.13 The manipulation of hydrogen bonding
and other intermolecular interactions to modify packing and
create new materials without altering the covalent chemistry is a
simple route to improve physical properties; e.g., larger
insoluble medicinal products can be engineered to have better
solubility characteristics.14
The development of industrial production of MCCs is
challenging due to many problems and pitfalls related to scaling
up their preparation. Even large scale crystallization of single
component systems can give rise to problems of physical purity
such as polymorphs, solvates, hydrates, and even amorphous
content, and these can be exacerbated, for multicomponent
systems, by the potential for crystals to have a varying
composition, such as 1:1 or 2:1 cocrystals or solid solutions,
giving rise to mixed phases. Many general crystallization
methods that are successful for discovery at laboratory scale,
such as solvent evaporation or antisolvent vapor diﬀusion, are
not seen as a viable solution for the large scale crystallization
process. Slurry-based methods are industrially feasible but suﬀer
from the fact that they are usually nonstoichiometric and
noncontinuous,15,16 which leads to diﬃculties with reproduci-
bility of particle size distribution and solid phase control.
Supercritical ﬂuid and twin-screw extrusion are other methods
for industrial scale production of multicomponent systems
which are reported as viable.17−19 Previous work by Zhao et al.
on cooling crystallization of a nutraceutical cocrystal has shown
that continuous crystallization in an oscillatory baﬄed reactor
oﬀers potential beneﬁts in terms of simplifying the scale-up and
reducing the time scales of process development from starting
materials to end product while retaining ﬁne control of the
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product quality.20 We have recently reported continuous
crystallization of 1:1 and 2:1 cocrystals of benzoic acid and
isonicotinamide via mixing-induced supersaturation using a
concentric capillary mixer.21 A key advantage is that continuous
processes operate at steady state which ensures consistency of
the ﬁnal product in terms of crystalline form and particle size
distribution and morphology.
Amino acids are crucial for maintenance of health and are
used extensively in foods, supplements, and medicines, and as
such their solid-state properties and structures have been
thoroughly investigated under a range of conditions.22−28 Very
few studies have investigated the amino acids in terms of the
production of MCCs and fully characterized the solid forms
despite the importance of these materials. A search of the
Cambridge Structural Database29 has shown that typically
structural studies have been limited to the crystallization of D-
and L-enantiomers together, a view supported by a recent
review of crystal structures of amino acids by Gorbitz.30 The
relatively low number of observations of structurally charac-
terized amino acid MMCs has largely been attributed to the
ineﬃcient packing that would result if single enantiomer
systems were crystallized together.31−38 However, there have
been a number of papers that have shown solid solutions exist.
For example, Kamei et al. investigated the solid−liquid
equilibria in L-isoleucine with L-alanine39 and L-norleucine40
and discovered that solid solutions of the systems exist through
the identiﬁcation of changes to the c-axis length on substitution
of norleucine into the system by monitoring the (1 0 0)
reﬂection using synchrotron radiation. With respect to the
systems discussed herein, Koolman and Rousseau investigated
the addition of small amounts of l-leucine and l-valine to 1-
isoleucine crystallizations and related the eﬀects of these
impurities on the morphology and size of the isoleucine to
possible substitution mechanisms in the crystal structure.41 It
was also shown via powder X-ray diﬀraction (PXRD) and
HPLC methods that solid solutions of L-valine, 1-isoleucine,
and l-leucine can be formed although limited structural data
were provided where the crystal structures of the solid solutions
were assumed to be the same as those of the pure amino
acids.42 Very recently, a further study of L-isoleucine and L-
valine solid solutions by Isakov et al. has detailed the phase
behavior of this system in water and identiﬁed a new crystal
structure associated with this complex.43 Again, chromato-
graphic and diﬀraction techniques were used to identify the
species involved.
Herein we report a rapid and reproducible continuous
antisolvent crystallization method to prepare solid solutions of
hydrophobic amino acids: L-valine, L-leucine, and L-isoleucine
(Scheme 1). Furthermore, we have identiﬁed new crystal
structures of L-leucine/L-isoleucine and L-leucine/L-valine as
well as conﬁrming the recent report of a new form of L-
isoleucine/L-valine.
■ EXPERIMENTAL SECTION
Solid Solution Formation. Solid solutions of each pair of amino
acids (≥98%, Sigma-Aldrich) were prepared using antisolvent
crystallization on a 200 mL scale. An undersaturated aqueous solution
was created by dissolving speciﬁc molar ratios of both amino acids in
water (90:10, 70:30, 50:50, 30:70, and 10:90 molar ratio). For each
pair of amino acids and deﬁned composition, chilled antisolvent
(isopropanol, Fisher Scientiﬁc) was added to the aqueous solution
under agitation by a magnetic stirrer. The antisolvent was added all at
once, resulting in a 95%w/w isopropanol solvent mixture. The
resulting solid product was ﬁltered and dried for analysis. The solid
produced from these antisolvent crystallizations was used to determine
the composition of the solid solutions and correlate it with the X-ray
diﬀraction data.
Continuous Antisolvent Crystallization. For the continuous
process, two diﬀerent stoichiometric ratios were used to demonstrate
the translation to a continuous antisolvent crystallization process. A
process ﬂow diagram of the continuous antisolvent crystallization
process used here is shown in Figure 1. In this process, a preheated
aqueous solution of amino acids at the required stoichiometric ratio
(stream 1 at 45 °C) was continuously injected through a submerged
stainless steel nozzle into the solution in the crystallizer vessel (V3)
with a liquid volume of 50 mL. A ﬂow rate (5 g/min) of stream 1 was
delivered and controlled by an Ismatec external gear pumps (MCP-Z)
with a magnetically coupled pump head (P1). The heat exchanger
(E1) warmed the ﬂuid and created a relative undersaturation of 0.4−
0.5. Nozzles with two diﬀerent internal diameters (0.2 and 0.6 mm) in
connection with stream 1 ﬂow rates generated diﬀerent jet injection
velocities (1.1−8.0 m/s) into the solution. Cold antisolvent
isopropanol (stream 2 between 3.4 and 4.5 °C) with the ﬂow rate
of 95 g/min entered the crystallizer (V3) through Marprene tubing
falling from the top of the vessel. The ﬂow rates of stream 2 were
delivered and controlled by a Watson-Marlow 520S peristaltic pump
(P2) so that a constant mixing ratio of the two inlet streams 1 and 2
was maintained. The resulting temperature in the crystallizer was kept
constant throughout the process (20 °C). This was achieved by
balancing temperatures of colder inlet streams with an external jacket
operating at a higher temperature (55 °C). Since the mean residence
time in the crystallizer was very short, there was a signiﬁcant
temperature diﬀerence between the solution in the crystallizer and the
vessel wall heated by the jacket. The reason for this was to minimize
supersaturation at the vessel walls in order to decrease a propensity for
fouling which would interfere with extended operation of the
crystallizer in a continuous mode. Fouling was further prevented by
immersing the crystallizer vessel in an ultrasonic bath (40 kHz, 50 W),
which was operated while the continuous crystallization was running.
The mean residence time in the crystallizer was 30 s, and the outlet
stream was continuously withdrawn to a storage vessel where it was
collected before subsequent ﬁltration and drying. After relatively short
transition times (up to 20 min), steady state operation of the
crystallizer was achieved, where a crystal slurry was present in the
crystallizer, and solid mass and crystallinity were not changing with
time anymore during the subsequent steady state operation. Thus, a
consistent quality of the solid phase product was achieved under
steady state conditions in the continuous operating mode. The
percentage yield for each compound can be found in Figure 2.
X-ray Diﬀraction Analysis. Single Crystal X-ray Diﬀraction
Analysis. A number of crystallizations have been performed to
crystallize the novel complexes. Initially equimolar quantities of two
amino acids (∼0.05 g, 0.4 mmol) were placed in a vial together with
water (5 mL), and heat was applied in order to complete dissolution.
After a period of a week at 25 °C, colorless crystals of suﬃcient quality
for single crystal diﬀraction appeared through evaporative crystal-
lization. Many crystallizations with varying ratios of components,
including saturated solutions of the components, were used. All these
crystallizations appeared to yield crystals of the same stoichiometry
Scheme 1. Molecular Form of (a) L-Leucine, (b) L-
Isoleucine, and (c) L-Valine
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except for compound 2 where one crystal (identiﬁed using the UK
National Crystallography Service) showed a diﬀerent composition to
that observed in our home laboratory. The details of the crystal
structure analysis can be found in the Supporting Information.
Crystal Structure Determination. X-ray diﬀraction intensities for L-
leucine/L-isoleucine (1), L-leucine/L-valine (2NCS), L-isoleucine/L-
valine (3) were collected at I19 at Diamond Light Source (1)44 and by
the National Crystallography service (2NCS and 3).45 X-ray diﬀraction
intensities for 2 were collected with Mo−Kα radiation on a Bruker
KAPPA Apex II CCD diﬀractometer equipped with an Oxford
Cryosystems Cryostream-Plus variable-temperature device operating at
−150 °C.46 Absorption corrections were carried out using the
multiscan procedure SADABS (Sheldrick, 2004, based on the
procedure described by Blessing, 1995).47,48 The structures were
solved by direct methods (SIR-92)49 and reﬁned by full-matrix least-
squares against F (I > 3σ) using all data (CRYSTALS).50 Because of
the wavelength of the source (0.71073 Å), the chirality of the amino
acids was assumed to be as stated by the manufacturer; however the
molecules were consistent with each other in the model; i.e., both
molecules were in the L-enantiomer.
The basic amino acid backbone (COO−C−N) and the ﬁrst carbon
of the chain were easily observed and used as the basic starting model
for the reﬁnements. From the diﬀerence map, extra peaks were
observed that were of the correct geometry to be assigned to be the
components of a speciﬁc amino acid. Once the two molecules were
identiﬁed, further diﬀerence maps were used to ﬁnd subsequent atoms
that could only be assigned to a second component. These diﬀerent
components were assigned part numbers. The bond distances of the
carbon side-chains (for compounds 1 and 2) were restrained to be
similar to those found in the Cambridge Structural Database29 (1.54 Å
for bonds between secondary carbons and 1.51 Å for bonds to primary
carbons). Thermal similarity and vibrational restraints were also
applied. The parts were given values of 50% occupancy and allowed to
reﬁne. 1 and 2 gave occupancy values that diﬀered slightly, and the
values quoted in the manuscript are average values with a standard
deviation. 3 was more straightforward with the reﬁnement remaining
at 50% for one of the molecules in the asymmetric unit. In this case
once the occupancy was established, the parts were not competitively
reﬁned. All hydrogen atoms attached to carbon atoms were
geometrically placed, and those participating in hydrogen bonding,
i.e., hydroxyl hydrogens, were found in the diﬀerence map. All non-H
atoms were modeled with anisotropic displacement parameters.
Additional programs used included Materials Mercury 2.4,51
PLATON as incorporated in WINGX.52,53 Mercury, ChemBioDraw
12.0, OriginPro 9.0, and Vesta were used in the production of the
ﬁgures.
Phase Analysis: Powder X-ray Diﬀraction. Laboratory Powder
Diﬀraction. A small quantity (1−50 mg) of each sample from the
antisolvent process was analyzed using PXRD data collected on a
Bruker AXS D2-Phaser equipped with primary monochromated
radiation (Cu−Kα1 λ = 1.54056 Å; 30 kV and 10 mA), a LYNXEYE
scintillation counter and rotating sample mount. Samples were ground
lightly before being mounted on a six-position sample holder. Data
Figure 1. Continuous crystallization system setup. An undersaturated aqueous solutions of amino acids was fed from the feed vessel (V1) through
the pump (P1) into the heat exchanger (E1) to heat to 45 °C before entering the crystallizer vessel (V3). Feed solution of isopropanol was fed
through E2 to cool to 3.4−4.5 °C before entering V3. The slurry of crystals was extracted from V3 by a pump (P3) into the collection vessel (V4).
Figure 2. Particle size distribution for compound (a) 1, (b) 2, and (c) 3 over time (top) using laser diﬀraction and yields from the continuous
process (50:50 molar ratio, bottom).
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were collected from each sample in the range 4−35° 2θ with a 0.01°
2θ step size and 1 s step−1 count time.
Synchrotron Powder X-ray Diﬀraction. PXRD data were collected
at −150 °C for the powder produced from the initial equimolar
(50:50) antisolvent crystallization for compounds 1, 2, and 3 using
Beamline I11 (HRPD) at the Diamond Light Source, Didcot, UK (λ =
0.826136(2) Å).54,55 Samples were densely packed into 0.7 mm
diameter thin-walled glass capillaries.
HPLC. HPLC with mass spectrometric detection was used to
analyze the composition of the complexes from the batch antisolvent
crystallization where the initial feedstock compositions were varied.
Stock solutions of each amino acid were prepared by dissolving
Figure 3. Pawley ﬁts of the diﬀraction data from I11 for compounds 1 (top), 2 (middle), and 3 (bottom) obtained from continuous process (50:50
molar ratio) using the unit cell parameters from our single crystal work. The d-spacings correlate well with a 50% content of each component for
each compound calculated from the batch experiments.
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suitable amounts in HPLC grade water (Waters Milli-Q). (Note: 2%
v/v acetonitrile was added to each amino acid solution prior to making
to volume to aid dissolution.) Mixed working standards of the two
required amino acids were prepared by diluting the stock solution with
80:20 acetonitrile/water such that the concentrations were in the
range ∼1−10 or 1−12 μg/mL. Two chromatographic systems were
used for the analysis. Compounds 1 and 2 were analyzed using an
isocratic HPLC system. This system consisted of an Agilent 1260
inﬁnity HPLC (Agilent Technologies LDA UK Limited, Stockport,
Cheshire, UK). The mobile phase was 20% 50 mM ammonium
formate in water and 80% acetonitrile at a ﬂow rate of 500 μL/min. A
SeQuant ZIC-HILIC column (HiChrom, Theale, Berkshire) was used
(150 × 4.6 mm, 5 μm particle size) at a temperature of 30 °C. The
injection volume was 10 μL. Detection of the amino acids was
achieved using an Agilent 6460 Triple Quad mass spectrometer
(Agilent Technologies LDA UK Limited, Stockport, Cheshire, UK)
equipped with an electrospray source. The electrospray needle was
maintained at 2.5 kV. The gas temperature was 300 °C. Nebulizing gas
and sheath gas ﬂows were at 3 L/min and 4 L/min, respectively. The
mass spectrometer was operated under MRM mode with the
fragmentor set at 135 and the collision energy set at 20. The mass
transitions (precursor → product) monitored were m/z 132 → 86 for
leucine and isoleucine and 118 → 72 for valine. The approximate
retention times were 9.4 min (leucine), 10.0 min (isoleucine), and
12.5 min (valine). Valine was well resolved (Rs > 4) from the other
two components, and leucine and isoleucine also showed acceptable
resolution (Rs = 1.56).
For compound 3 a gradient HPLC method was used for the
analysis. This system consisted of a Thermo Finnigan Surveyor HPLC
(ThermoFisher Scientiﬁc, Altrincham, Cheshire, UK). The mobile
phases for HPLC were (A) 20 mM ammonium carbonate in water and
(B) acetonitrile. Gradient runs were programmed using a linear
gradient from 20% B to 50% B over 30 min at a ﬂow of 300 μL/min.
The equilibration time of the column between injections was 8 min. A
SeQuant ZIC-pHILIC column (HiChrom, Theale, Berkshire) was
used (150 × 4.6 mm, 5 μm particle size) at ambient temperature
(approximately 20 °C). The injection volume was 2 μL. Detection of
the amino acids was achieved using a Finnegan LTQ Orbitrap Fourier-
Transform mass spectrometer (ThermoFisher Scientiﬁc, Altrincham,
Cheshire, UK) equipped with an electrospray source. The electrospray
needle was maintained at 4.5 kV and 275 °C. Sheath and auxiliary gas
ﬂows were set at 50 and 15 respectively. A full mass scan was
performed in positive ion mode with a mass range of m/z 100−1200,
and the resolution was 30000. Extracted ions at m/z 118.09 (valine)
and m/z 132.1 isoleucine) were used for quantiﬁcation purposes. The
approximate retention times were 9.7 min (isoleucine) and 11.1 min
(valine). Valine and isoleucine were baseline resolved (Rs > 2).
Typical calibration lines used in the sample analysis can be found in
Table ES2. Recoveries were conﬁrmed using separately prepared
standard solutions.
Particle Size Distribution. A Malvern Mastersizer (APA2000,
Malvern Instruments Ltd., UK) laser diﬀraction instrument was used
to determine the particle size distribution of solid powder samples.
The instrument was conditioned with mother-liquor from the
crystallization experiment to account for background scattering. The
sample crystal slurries from the crystallizer outlet tube were pipetted
into the Mastersizer sample container unit until the instrument
indicated that the optimum solid concentration had been achieved for
a measurement. The refractive index of 1.65 was used for the
measurement and data analysis.
■ RESULTS AND DISCUSSION
Identiﬁcation of the Solid Solution. Previous work by
Kurosawa et al.42 and Isakov et al.43 has shown that the three
amino acids, L-leucine, L-isoleucine, and L-valine, formed solid
solutions via the interpretation of the (0 0 1) reﬂection from
the PXRD patterns and HPLC methods. One of the limitations
of the Kurosawa paper was that they assumed that the crystal
structure of the materials remained the same at each
composition. This was rectiﬁed for the isoleucine/valine system
where Isakov and co-workers identiﬁed a new crystal form, a C-
Table 1. Crystal Solid Yield at Various Experimental
Runtimes
solid yield [%]
time [min] 1 2 3
1 0.0 4.0 3.4
3 3.0 50.3 26.3
10 24.6 50.6 67.3
30 67.8 53.8 67.7
100 72.2 54.9 70.8
Figure 4. Waterfall plots of the three compounds with varying molar
ratio composition (refer to Table 2 for exact composition identiﬁed in
HPLC). The change in the peak positions indicating the slow change
in the unit cell parameters with addition of a second component.
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centered cell related to the basic amino acid unit cells. At the
same time, through small scale batch evaporative crystalliza-
tions, we have been able to isolate crystals of the solid solutions
of leucine/isoleucine (1), leucine/valine (2), and isoleucine/
valine (3) with unit cell lengths close to the original phases but
with a diﬀerent β-angle. The structures were initially elucidated
using single crystal X-ray diﬀraction using data collected by the
National Crystallography Service (NCS)45 and Diamond Light
Source Rapid Access Service (RAS) at beamline I19.56 After a
period of two months in solution, the crystal quality improved
through annealing processes such that in-house data could be
used to help verify the quantities of each component and
conﬁrm the NCS and RAS data. The proportion of each
constituent is not stoichiometric, and therefore ﬁve data sets
were collected for each sample in order to be sure of the
proportion of each amino acid within the crystals in each batch.
The percentage composition in 1 is 59(2)% isoleucine, 2 is
61(3)% leucine, and 3 is 75% valine. The composition of the
latter did not show any variation between data sets and was
ﬁxed hence no error. Interestingly, for 2, the extent of this
disorder altered slightly over time. Analysis of small less mature
crystals using NCS showed that the percentage occupancy for 2
was 73:27 leucine/valine cf. 61:39 from more mature crystals,
indicating the change in the composition of the solution.
The unit cells of all three solid solutions are diﬀerent from
their parent compounds with a signiﬁcant change in the β-angle
of the cell for compounds 1 and 2, and there is an addition of
C-centring in compound 3, so while the unit cell dimensions
are similar the packing of the molecules has been altered by the
addition of a second component in line with the observations of
Isakov et al. These observations are contrary to the assumptions
made by Kurosawa et al. that the crystal structure was the same
as the pure phases; nevertheless we do observe the non-
stoichiometric quantities of materials indicating the solid
solution have been formed. Compounds 1 (Figure ESI) and
2 crystallize in P21, while compound 3 crystallizes in C2 with all
forms possessing two molecules in the asymmetric unit. The
basic amino acid hydrogen bonded chains exist in all three
complexes and have a consistent geometry compared with the
hydrogen bonding observed in the pure amino acid structures;
i.e., the disorder that has arisen due to the cocrystallization
process has not aﬀected these stronger intermolecular
interactions.57−59 The overall structure of the materials remains
as a bilayer where head groups interact via hydrogen bonding
with those of neighboring chains and the hydrophobic tail
groups of the amino acids interact with those of a diﬀerent
chain. The crystallographic information can be found in the
Supporting Information.
Antisolvent Crystallization. Having established that the
solid solutions of the three compounds crystallized in diﬀerent
crystal structures, we investigated the ability of continuous
antisolvent preparative routes to form these complex systems.
The ﬂexibility of the continuous approach is ideal for the
production of these solid solution phases; the short residence
times means that the composition of the resulting solid solution
can be varied and tuned rapidly. This method was chosen as
established synthetic routes; e.g., ball-milling, liquid-assisted
grinding, and slurry methods, failed to produce pure products.
Starting with two diﬀerent molar ratios of the two
components, 50:50 and 40:60, in the inlet stream 1, we used
the continuous antisolvent approach to produce gram
quantities. The analysis using PXRD (Diamond Light Source,
Figure 3), particle size distribution and yield present here were
performed on the 50:50 ratio. The mean residence time in the
crystallizer was 30 s where the product was continuously
withdrawn to a storage vessel. After approximately 20 min,
steady state operation of the crystallizer was achieved, where a
slurry was present in the crystallizer and particle size
distribution was not changing with time (Figure 2). Thus, a
consistent quality of the product was achieved under steady
state conditions in the continuous operating mode. The
continuous process provided steady-state yields (based on the
total amount of amino acids in the inlet feed) of 70% for 1, 50%
for 2, and 70% for 3 were observed after experimental running
times of 20, 3, and 10 min, respectively (Table 1 and Figure 2).
These yields can be further improved by varying the solvent to
antisolvent ratio. Figure 2 shows the particle size distributions
for the crystals produced in the crystallizer (rather that the
storage vessel) where the time indicated represents the runtime
of the experiment. One can observe the reduction in the
number of smaller crystallites during the continuous process
such that by 10 min a steady particle size was being produced
with a small portion of crystallites with smaller dimensions. The
particle sizes showed an asymmetric distribution skewed to
Table 2. Position of the (0 0 1) Reﬂection ((2 0 0) for
Compound 3) for Each Compound, Obtained from Pawley
Fits to the Room Temperature Data, with Respect to the
Concentration of the Reactantsa
compound 1 leucine %
content (mass spec.)
d-spacing
observed structure
d-spacing of Kurosawa et
al. with % leucine/
isoleucine
0 13.9441 IL
10.12 13.98 SS 14.24 (14%)
31.40 14.16 SS 14.48 (34%)
51.15 14.29 SS 14.52 (46%)
68.67 14.39 SS 14.56 (60%)
92.05 14.55 SS 14.80 (91%)
100 14.6260 L
compound 2 leucine %
content (mass spec.)
d-spacing
observed structure
d-spacing of Kurosawa et
al. with % leucine/
isoleucine
0 12.0661 V
7.43 12.15 V 12.50 (13%)
34.04 13.03 SS 13.04 (28%)
52.06 13.47 SS 13.37 (45%)
74.34 14.04 SS 14.32 (77%)
94.14 14.41 SS 14.56 (92%)
100 14.6260 L
compound 3 hypothetical
isoleucine % content
d-spacing
observed structure
d-spacing of Kurosawa et
al. with % leucine/
isoleucine
0 12.0661 V
10.90 12.35 V 12.36 (11%)
35.59 12.83 SS 12.80 (28%)
51.50 13.08 SS 13.23 (58%)
75.87 13.62 SS 13.34 (89%)
75.87 14.08 IL 13.99 (89%)
87.56 13.80 SS 13.26 (95%)
87.56 14.03 IL 14.01 (95%)
100 13.9441 IL
aThe crystal structure that was used to ﬁt the data are presented
alongside the results of Kurosawa et al. The values in parentheses are
the percentage of leucine or isoleucine corresponding to their X-ray
data.
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smaller sizes with a mode being around 40, 25, 50 μm for 1, 2,
and 3, respectively.
Identiﬁcation of Solid Phase from Continuous
Process. The solids produced from the continuous antisolvent
crystallization (50:50 ratio) were analyzed via PXRD and
Pawley ﬁtted against the known phases including the new
structures identiﬁed in this paper. Figure 3 shows a Pawley ﬁt of
the PXRD data collected at I11, Diamond Light Source (−150
°C; λ = 0.826939 Å) using cell parameters of the novel phases
1−3. These data are collected at −150 °C and therefore show a
slight shift with respect to the results of Kurosawa et al.42 and
Isakov et al.43 There are a number of tick marks between 2θ
values of 4−8° which have near zero intensity, which is
representative of the structure.
Correlation of Solid Solution Composition and X-ray
Diﬀraction Data. A more extensive analysis of the solid
solutions was performed using products from the batch
antisolvent experiments to correlate the PXRD pattern to the
solid solution composition so that a comparison with the
methodologies in the literature could be performed (Figure 4).
Table 2 shows the proportions of each component (as
identiﬁed by HPLC) as a function of the d-spacing observed
(20 °C) and the type of structure that ﬁts the data, e.g., pure
components or solid solution. These data are also compared
with those of Kurosawa in which we have used data for the
samples of similar composition. The HPLC was performed
without modiﬁcation of the amino acids unlike previous work
where the amino acids were subject to prederivatization using
o-phthaldialdehyde; we have avoided this step by using the
ZIC-HILIC column that allows clear separation of the amino
acids, even leucine and isoleucine.
For compound 1 we observe that the solid solution phase
can be ﬁt to all our data at various compositions. It is clear that
our data and that of Kurosawa et al.42 are substantially diﬀerent
from one another with ours showing a much more linear
change with composition (Figure 5). Both studies observe only
one peak, which suggests that the phases that were produced
were pure. This reﬂects the subtle diﬀerences in the molecular
structure of the two components. Isoleucine and leucine are the
same size of molecule with a diﬀerence in the connectivity of
the tail group. Substitution of isoleucine into the leucine
structure has caused a change in the unit cell parameters mainly
in the β-angle 104° cf. 94.06°.60
The diﬀraction and composition data for compound 2 from
our study ﬁts well with previous work showing a linear change
of the d-spacing with the composition of the solid; however at
10% leucine the structure reverts to the valine structure as
identiﬁed by the unit cell parameters. Again there is a shift in
the β-angle to 109° from ∼94° and 90° for leucine and valine
unit cell parameters, respectively.
Compound 3 shows some indication that toward 100%
composition of isoleucine there is a mixed phase with the solid
solution and the pure isoleucine solids; this is in line with the
observations of Isakov et al.43 The HPLC reveals that our
composition is a reasonably good ﬁt to the ideal values, i.e., 10,
30, 50, 70, and 90%. We also observe a biphasic nature down to
75% isoleucine with the second phase ﬁtting the unit cell
parameters of pure isoleucine Form I. Our data for compound
3 follows that of Kurosawa42 until there is a greater quantity of
Figure 5. Plots of the (1 0 0) or (2 0 0) reﬂection vs % composition observed for our data (black squares) and that of Kurosawa (red circles).42
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isoleucine (89 and 95%). At this point their data fall away from
the projected movement, while our data remain in line with
what one would suspect for a solid solution. In terms of the
composition of the solid we have identiﬁed it is a 3:1 valine/
isoleucine (75%) solid solution which is at the extremity of the
V2I phase that Isakov highlighted in their study; however
interestingly the unit cell is larger in our case (both studies were
collected at −173 °C), which is counterintuitive given there is a
greater portion of the smaller constituent. The packing is
similar, bearing in mind the discrepancy of chirality from the
structure in the CSD (ALIHUA), with no particular features
that are diﬀerent to guide any reasonable argument as to the
diﬀerences. The previous determination has both molecules
substituted with isoleucine contrary to our determination but
despite this the a-axis (where the tails group interact) is longer.
One methodological note to make, that may impact our
results compared with that of Isakov et al.,43 is that the resulting
solid from our experiment was harvested from solution and was
not ever subject to complete evaporation unlike the previous
study; hence the solubility of the initial components during the
antisolvent crystallization will have an impact on the resulting
solid collected. The solubility of the solid solution was shown
by Isakov to be higher than the isoleucine solubility, hence the
reason that we observe the mixed phase in the solid.
■ CONCLUSIONS
This study has shown that we are able to control the formation
of tunable solid solutions of hydrophobic amino acids using a
novel antisolvent crystallization approach. We have also shown
that solid solutions can be formed easily and rapidly through
continuous antisolvent crystallization. The continuous process
is rapid, since the mean residence time in the crystallizer is only
30 s, and it can run at steady state over extended periods of
time, oﬀering considerable advantages over traditional batch
based scale up approaches. In high value chemicals manufactur-
ing, reproducibility is a key attribute and can be achieved
through continuous operation at steady state. The develop-
ment, testing, and implementation of continuous crystallization
approaches are of particular importance in light of increased
interest in continuous manufacturing processes for pharma-
ceuticals, and other high value chemical products can be formed
routinely using continuous antisolvent crystallization.
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